Is BPC-157 legal in Australia?

The short answer

In Australia, BPC-157 is a Schedule 4 (Prescription Only Medicine) substance under the Poisons Standard and is also listed in Appendix D. It is not approved by the TGA for human therapeutic use, is not on the Australian Register of Therapeutic Goods, and cannot be lawfully sold as a medicine or supplement. NovaPeptides supplies it strictly for laboratory research use only.

How the TGA classifies BPC-157

On 1 June 2024, BPC-157 was added to the Australian Poisons Standard via the Therapeutic Goods (Poisons Standard - June 2024) Instrument. It was placed in Schedule 4, which covers Prescription Only Medicines, and also added to Appendix D, the part of the Standard listing substances whose possession without authority is restricted. Australia was the first country in the world to schedule BPC-157 specifically by name.

Being in Schedule 4 means BPC-157 is treated as a prescription-only substance rather than something freely available over the counter or as a wellness supplement. Its inclusion in Appendix D adds a further layer of control around possession. This status is confirmed by government-aligned sources including the TGA final decision, Sport Integrity Australia, and Healthy Male.

Schedule 4 (Prescription Only Medicine) plus Appendix D, effective 1 June 2024.

You may see older or third-party blog posts describing BPC-157 as unscheduled, or as Schedule 9 (prohibited). Both are incorrect. The confirmed, current status is Schedule 4 plus Appendix D. When in doubt, the authoritative reference is the TGA Poisons Standard itself.

Not approved and not on the ARTG

Separate from its scheduling, BPC-157 is not approved by the TGA for human therapeutic use and is not listed on the Australian Register of Therapeutic Goods (the ARTG). The ARTG is the official register of medicines and therapeutic goods that may be lawfully marketed in Australia. Because BPC-157 is not on it, it cannot lawfully be sold or supplied as a medicine, therapeutic good, or dietary supplement for human use.

This is the core distinction for anyone trying to understand its legal status. Scheduling describes how the substance is controlled. The ARTG describes whether a finished product has been assessed and approved for sale. BPC-157 fails the second test: no BPC-157 product has completed TGA assessment for quality, safety, and efficacy as a human medicine.

Research compound vs approved medicine

Understanding BPC-157 in Australia comes down to one idea: it sits in the research-compound category, not the approved-medicine category. These are two very different regulatory worlds, and the table below sets out how they differ.

An approved medicine has been through the full TGA pathway, carries a regulated label and consumer medicine information, and can be prescribed and dispensed. A research compound has not completed that pathway. It is supplied for laboratory and in-vitro study, makes no approved human therapeutic claims, and is not a substitute for a registered medicine. BPC-157 falls squarely into this second category in Australia.

What research use only (RUO) actually means

Research Use Only is a regulatory designation. It indicates that a product is supplied strictly for laboratory and in-vitro research and is not intended, tested, or approved for human or veterinary use, diagnosis, or treatment. RUO products carry prominent For Research Use Only. Not for human use labelling, and that label is meant literally.

• Supplied for laboratory and in-vitro research, not human or veterinary use
• Not assessed or approved for diagnosis, treatment, or therapy
• Carries clear For Research Use Only. Not for human use labelling
• Does not make, and cannot make, approved human therapeutic claims

What BPC-157 is and what the science actually shows

BPC-157 is a synthetic, stable pentadecapeptide, meaning a chain of 15 amino acids. It is described as a partial sequence derived from a body protection compound identified in gastric juice. In preclinical models it has been studied for tissue and wound healing and for angiogenesis, the formation of new blood vessels.

It is important to be honest about the strength of that evidence. Most of the published research is preclinical, and chiefly animal, primarily rat studies on tendon, ligament, muscle, and wound healing. Human clinical trial data is very limited. Healthy Male, an Australian government-funded men's health organisation, has noted a concerning lack of published clinical trial data, with studies appearing to have stopped without published conclusions, and states there is not enough evidence of its safety.

BPC-157 and sport: the WADA and anti-doping angle

Many people searching whether BPC-157 is banned are asking about sport, so this is worth covering directly. BPC-157 is on the World Anti-Doping Agency (WADA) Prohibited List under category S0, Non-Approved Substances, prohibited at all times, both in and out of competition. That status has been in effect since 1 January 2022.

Sport Integrity Australia enforces the Prohibited List in Australia and has stated that a Therapeutic Use Exemption (TUE) would not be granted for BPC-157 for any medical condition. Athletes subject to anti-doping rules who use BPC-157 risk sanctions and bans. This is stated here as neutral fact, not as encouragement of any kind.

Prohibited at all times under category S0, in effect since 1 January 2022. No TUE available.

A note on personal importation

People sometimes ask whether BPC-157 can be brought in under the TGA Personal Importation Scheme. As a factual matter, that scheme is generally designed for goods not available locally and usually requires a valid Australian prescription or authority, and it is structured around overseas-approved medicines. Because BPC-157 is Schedule 4 plus Appendix D and is not on the ARTG, it does not fit that scheme the way an overseas-approved medicine would.

We describe this situation factually only. This page does not provide import instructions, prescription workarounds, dosing guidance, or any how-to-obtain-it-for-personal-use information. For anything touching your own circumstances, the right step is to speak to the TGA or a qualified professional.

How NovaPeptides supplies BPC-157

NovaPeptides supplies BPC-157 explicitly for research use only, never for human use. Every batch is independently verified, ships within Australia, and enquiries are handled directly over WhatsApp. We do not make medical claims, do not list it as a consumer or therapeutic product, and do not offer dosing for human use.

• Supplied strictly for laboratory research use only, not for human consumption
• Independently lab-tested with a Janoshik third-party Certificate of Analysis (COA) verifying identity and purity
• Ships within Australia from the Gold Coast
• Research enquiries handled via WhatsApp

Frequently asked questions